n, staging and treatment of melanoma that are central to making further clinical advances against this disease", said MRA Chief Science Officer Dr. Suzanne L. Topalian. "This is a time of unprecedented opportunity in melanoma research, and these projects are anticipated to result in near-term benefits for patients.

n, staging and treatment of melanoma that are central to making further clinical advances against this disease", said MRA Chief Science Officer Dr. Suzanne L. Topalian. "This is a time of unprecedented opportunity in melanoma research, and these projects arc anticipated to result in near-term benefits for patients.